Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
These accolades highlight our unwavering commitment to maintaining the highest safety standards
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
Sigachi's entry into the coatings market is strategically timed to capitalize on the industry's growth potential
This is in partnership with Mepro Pharmaceuticals which have successfully developed and commercialised the Albendazole Chewable formulation
Subscribe To Our Newsletter & Stay Updated
